
|Articles|October 1, 2003
Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate
Advertisement
Articles in this issue
almost 22 years ago
Participating Facultyalmost 22 years ago
Defining and Characterizing the Late-stage Biopharmaceutical PipelineNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5